Files and links (1)
Published, Version of Record (VoR)CC BY V4.0, Open
Journal article
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Rheumatology international, v 37(7), pp 1111-1123
Jul 2017
PMID: 28560470
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses a significant economic burden. The Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Subjects with Background Methotrexate (AMPLE) trial was a head-to-head, randomized study comparing abatacept in serum anti-citrullinated protein antibody (ACPA)-positive patients, with increasing efficacy across ACPA quartile levels. The aim of this study was to evaluate the cost per response accrued using abatacept versus adalimumab in ACPA-positive and ACPA-negative patients with RA from the health care perspective in Germany, Italy, Spain, the US and Canada. A cost-consequence analysis (CCA) was designed to compare the monthly costs per responding patient/patient in remission. Efficacy, safety and resource use inputs were based on the AMPLE trial. A one-way deterministic sensitivity analysis (OWSA) was also performed to assess the impact of model inputs on the results for total incremental costs. Cost per response in ACPA-positive patients favoured abatacept compared with adalimumab (ACR20, ACR90 and HAQ-DI). Subgroup analysis favoured abatacept with increasing stringency of response criteria and serum ACPA levels. Cost per remission (DAS28-CRP) favoured abatacept in ACPA-negative patients, while cost per CDAI and SDAI favoured abatacept in ACPA-positive patients. Abatacept was consistently favoured in ACPA-Q4 patients across all outcomes and countries. Cost savings were greater with abatacept when more stringent response criteria were applied and also with increasing ACPA levels, which could lead to a lower overall health care budget impact with abatacept compared with adalimumab.
Metrics
Details
- Title
- Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
- Creators
- Laure Weijers - Real World Strategy and Analytics, Mapi Group, Houten, The Netherlands.Christoph Baerwald - University Hospital LeipzigFrancesco S Mennini - EEHTA-CEIS, Faculty of Economics, University of Rome 'Tor Vergata', Rome Italy and Institute of Leadership and Management in Health, Kingston University, London, UK.José M Rodríguez-Heredia - Hospital Universitario de GetafeMartin J Bergman - Drexel UniversityDenis Choquette - University of MontrealKirsten H Herrmann - Bristol-Myers SquibbGiulia Attinà - Bristol-Myers SquibbCarmela Nappi - Bristol-Myers SquibbSilvia Jimenez Merino - Bristol-Myers SquibbChad Patel - Bristol-Myers SquibbMondher Mtibaa - Bristol-Myers SquibbJason Foo - Real World Strategy and Analytics, Mapi Group, Houten, The Netherlands.
- Publication Details
- Rheumatology international, v 37(7), pp 1111-1123
- Publisher
- Springer Nature
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:000404152100008
- Scopus ID
- 2-s2.0-85019738792
- Other Identifier
- 991019169795304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Rheumatology